FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Shuren Retiring; Tarver is Acting CDRH Director

CDRH director Jeff Shuren says he is retiring later this year and deputy Center director for transformation Michelle Tarver will serve as acting direc...

latest-news-card-1
Human Drugs

FDA Wants Host Cell Protein Immunogenicity Info

FDA establishes a docket for information and comments on evaluating and mitigating the immunogenicity risk of host cell proteins.

latest-news-card-1
Human Drugs

Biocon Biosphere FDA-483

FDA releases the form FDA-483 with three observations from an inspection at Biocon Biosphere in Andhra Pradesh, India.

latest-news-card-1
Human Drugs

Pfizer Optimistic on Hemphilia A Gene Therapy

Pfizer plans to discuss with FDA its path to seek approval of its investigational gene therapy for treating adults with moderately severe to severe he...

latest-news-card-1
Federal Register

Mesa Bio Covid Test Authorization Revoked

Federal Register notice: FDA announces that it revoked a Mesa Biotech emergency use authorization for the Accula SARS-CoV-2 Test.

latest-news-card-1
Biologics

FDA Seeks Input on Biosimilar Guidance Development

FDA establishes a docket to receive information and comments on how best to advance the development of new biosimilar biological products through guid...

latest-news-card-1
Human Drugs

RWD in Regulatory Decisions Guidance

FDA publishes a guidance on assessing types of medical records to provide real-world data (RWD) for drugs and biologics regulatory decision-making.

latest-news-card-1
Human Drugs

Glass Vial, Stopper Guidance

FDA publishes a guidance with recommendations for reporting categories and the content of postapproval change submissions about glass container closur...

latest-news-card-1

Common BIMO Violations Listed

Attorney Julie Tibbets reviews the Warning Letters issued in FY 2023 and so far in FY 2024 under the FDA Bioresearch Monitoring program.

latest-news-card-1
Human Drugs

FDA Denies Novartis Entresto Petition

FDA denies a Novartis 2022 petition seeking specific agency actions on ANDAs citing Entresto as the reference-listed drug.